CDKN3 and prostate cancer: The same article showed that suppressing CDKN3 promotes the proliferation of HCC cells and confers a diminished sensitivity to Adriamycin chemotherapy.[48] Overexpression of CDKN3 is associated with poor progression in prostate cancer and its inhibition significantly reduces cancer cell growth.